AT Impf

Europe, Bayern, Germany, Munich

Description

AT Impf was added in 2010.

Investor Profile

AT Impf has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

Concentrates on Series D, Post Ipo Equity, Series C rounds (top funding stages).
Majority of deals are located in Germany.
Strong thematic focus on Biotechnology, Medical, Therapeutics.

Stage Focus

Series D (33%)
Post Ipo Equity (17%)
Series C (17%)
Series E (17%)
Series Unknown (17%)

Country Focus

Germany (100%)

Industry Focus

Biotechnology
Medical
Therapeutics

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does AT Impf frequently co-invest with?

Wellington Partners

Europe, Bayern, Germany, Munich

Co-Investments: 5

dievini Hopp Biotech Holding

Europe, Baden-Wurttemberg, Germany, Walldorf

Co-Investments: 5

Amgen

North America, California, United States, Thousand Oaks

Co-Investments: 1

RTW Investments

North America, New York, United States, New York

Co-Investments: 1

Perceptive Advisors

North America, New York, United States, New York

Co-Investments: 1

Redmile Group

North America, California, United States, San Francisco

Co-Investments: 1

Sphera Funds Management

Asia, Tel Aviv, Israel, Tel Aviv

Co-Investments: 1

MIG Capital

Europe, Bayern, Germany, München

Co-Investments: 2

What are some of recent deals done by AT Impf?

immatics biotechnologies

Tübingen, Baden-Wurttemberg, Germany

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.